drugset / Trial / NCT05338034
Phase 2a Study of HPG1860 in Subjects With NASH
RandomizedParallel-groupQuadruple-blindPrevention
Summary
This is a Phase 2a, randomized, double-blind, placebo-controlled, parallel group, multiple arm, multicenter study of 3 different doses of HPG1860 versus placebo in subjects with biopsy-confirmed or phenotypic NASH.
Timeline
- Start
- 2021-11-22
- Primary completion
- 2023-02-28
- Completion
- 2023-03-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HPG1860 | Small molecule | 3 mg | Oral |
| Subject | HPG1860 | Small molecule | 5 mg | Oral |
| Subject | HPG1860 | Small molecule | 8 mg | Oral |